The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2021 | FOCUS4-C: Adavosertib in metastatic colorectal cancer
Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, discusses the results of the FOCUS4-C trial (EudraCT Number: 2012-005111-12), which assessed the WEE1 inhibitor adavosertib in patients with newly diagnosed TP53- and RAS-mutant metastatic colorectal cancer. Patients initially received 16 weeks of chemotherapy and then received adavosertib or active monitoring. The primary endpoint of progression-free survival (PFS) was met in the adavosertib arm, and adavosertib particularly benefited patients with left-sided primary tumors or KRAS exon 12/13 mutations. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.
Disclosures
Dr Seligmann has received honoraria/travel/consultancy fees from Servier, Merck Serono, Pierre Fabre, Roche Diagnostics, BMS, and GI Connect.
